We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




First US Use of Patient's Own Stem Cells to Repair Heart

By HospiMedica staff writers
Posted on 24 Mar 2003
For the first time in the United States, doctors have used bone marrow stem cells from a patient's own blood to repair heart damage resulting from a heart attack. More...
The doctors hope the stem cells will regenerate damaged heart tissue and stimulate the growth of new blood vessels.

The patient, a boy of 16, suffered a massive heart attack caused by swelling that caused pressure on his coronary artery, leaving him with no option but a heart transplant. By coincidence, doctors at the hospital had been preparing for a clinical trial of stem cells. The experimental treatment began with putting the patient on a four-day regimen of a drug (Neupogen) that stimulates the production of stem cells. Four days later, they harvested the patient's stem cells with a special blood collection machine, then used a heart catheter to transplant the stem cells into the patient's left anterior descending artery, which supplies blood to the heart.

Although there is no proof as yet that the therapy is working, doctors report that the patient's ejection fraction, which had fallen from 65-25%, rose to 35% several days after the operation. Positron emission tomography (PET) scans taken prior to the procedure showed no viable heart muscle in the area affected. The doctors plan to take another scan in three months to determine if new muscle is shown there as a result of the treatment.

"The transplant went exactly as planned, lasting less than 60 minutes,” says Steven Timmis, M.D., who performed the stem cell transplant at Beaumont Hospital in Royal Oak (MI, USA). "Dimitri tolerated the treatment very well, experiencing no complications.”




Related Links:
Beaumont Hospitals

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
LED Surgical Lamp
ACEMST35/57
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.